retatrutide dosing phase 2 trial FDA Approval Status 2026: Everything We Know So Far A Clinician's Guide to Retatrutide

The longest of the trials (SURMOUNT-4) reported weight loss of -20.9% within 36 weeks and an additional -5.5% (total of -25.4%) within 88 weeks of administration [20]

Regulators focus on substance, use, and context rather than disclaimers

Just maintain a straightforward journal of dose, timing, symptoms, menstrual/ovulation markers, and quantifiable things like basal body temperature or salivary hormone tests

As a general rule, these compounds can be categorised as short-acting (predominant activity on post-meal glycaemic rises) and long-acting GLP-1 analogues (24 h active with predominant effect on fasting glucose and somewhat reduced effectiveness on post-meal glycaemic excursions) [4]